Who makes BI 653048 BS H3PO4?

BI 653048 BS H3PO4 is developed by Boehringer Ingelheim.

What development phase is BI 653048 BS H3PO4 in?

BI 653048 BS H3PO4 is in Phase 1.

Last reviewed 2026-04-20 · How we verify

BI 653048 BS H3PO4

Boehringer Ingelheim · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	BI 653048 BS H3PO4
Sponsor	Boehringer Ingelheim
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BI 653048 BS H3PO4 Capsule Assessing Endotoxin-induced Inflammatory Response in Healthy Male Subjects (PHASE1)
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 653048 BS H3PO4 Capsule Multiple Rising Doses in Healthy Male Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BI 653048 BS H3PO4 CI brief — competitive landscape report
BI 653048 BS H3PO4 updates RSS · CI watch RSS
Boehringer Ingelheim portfolio CI